<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10042">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068105</url>
  </required_header>
  <id_info>
    <org_study_id>ALK5461-209</org_study_id>
    <nct_id>NCT02068105</nct_id>
  </id_info>
  <brief_title>A Study of ALKS 5461 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Two-part Study to Evaluate the Relative Bioavailability of Two Formulations of ALKS 5461 and the Effect of Dose Titration of ALKS 5461 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to test the safety of ALKS 5461 in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Relative bioavailability of ALKS 5461 treatment groups</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The parameters for determining the bioavailability include Cmax, AUC last, and AUC(0-infinity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability:  Incidence of adverse events</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>ALKS 5461-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 5461</intervention_name>
    <description>Sublingual tablet</description>
    <arm_group_label>ALKS 5461-A</arm_group_label>
    <arm_group_label>ALKS 5461-B</arm_group_label>
    <arm_group_label>ALKS 5461 Dose 1</arm_group_label>
    <arm_group_label>ALKS 5461 Dose 2</arm_group_label>
    <arm_group_label>ALKS 5461 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sublingual tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be in good physical health

          -  Body mass index of 18-30 kg/m2

          -  Agree to use an approved method of birth control for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Currently pregnant or breastfeeding

          -  History of or current infection with Hepatitis B Virus, Hepatitis C Virus or Human
             Immunodeficiency Virus (HIV)

          -  Current or history of any clinically significant medical or psychiatric condition

          -  Current abuse or dependence on alcohol or any illicit drugs

          -  Have used nicotine within 90 days

          -  Have used St. John's Wort or consumed grapefruit, grapefruit juice, or juices
             containing grapefruit within 30 days

          -  Have used any prescription or over-the-counter medication, including natural health
             products (with the exception of prescription birth control or hormonal replacements,
             acetaminophen, ibuprofen, or multivitamins) within 14 days

          -  Have used opioids 30 days prior to screening or have an anticipated need for opioid
             medication at any point during the study

          -  Have a history of intolerance or hypersensitivity to buprenorphine or opioid
             antagonists (eg, naltrexone, naloxone)

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Marshall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALKS 5461</keyword>
  <keyword>samidorphan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
